Loading...

Buy Full Version
"Japan Oncology Drugs Market"

Let us help you !

Invalid Email.

Please Select Country.

Invalid contact no.

Special Symbols Not Allowed.

Invalid Security Code.

Thank You For Your Interest.

We've Successfully Got Your Message,

Our Executive will get back to you Shortly.

Japan Oncology Drugs Market by Drug Class Type (Chemotherapy, Targeted Therapy, Immunotherapy, and Hormonal Therapy), and Indication (Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Lung Cancer, Skin Cancer, Ovarian Cancer, Cervical Cancer, Kidney Cancer, and Other Cancers): Opportunity Analysis and Industry Forecast, 2019–2026

LI_195642
Pages: 147
Aug 2019 | 452 Views
 
Author(s) : Sagar Mukhekar , Onkar Sumant
Tables: 29
Charts: 56
 

Japan Oncology Drugs Market Outlook - 2026

The Japan oncology drugs market size was accounted for $9,405 million in 2018, and is expected to reach $14,109 million by 2026, registering a CAGR of 5.2% from 2019 to 2026. 

Cancer is a chronic medical condition that involves an abnormal growth of cells. The abnormal growth of cells results in the formation of a tumor. Furthermore, these abnormal tumor cells have the tendency to spread to other local tissues through blood and lymphatic system. Different types of cancers such as colorectal, stomach cancer and others are predominant among the Japanese populace. Treatment of cancer depends upon the stages of the disease progression. Chemotherapy is majorly used in the earlier stages whereas other therapy options such as targeted therapy drugs, immunological therapy drugs are used in late stage. 

Japan Oncology Drugs Market

Get more information on this report : Request Sample Pages

Rise in incidence of cancer in Japan, surge in research related to new drug discovery for cancer treatment, and increase in healthcare expenditure are the major factors that fuel the growth of the Japan oncology drugs market. In addition, surge in awareness related to early diagnosis of cancer leading to rise in demand for oncology drugs for treatment boost the growth of the market in Japan. Furthermore, surge in geriatric population also contributes to the growth of the market as the elderly are more prone to certain cancers such as prostate cancer. In addition, rise in number of pipeline products is expected to provide lucrative opportunities during the forecast period. However, stringent approval process of oncology drugs in Japan hinders the growth of the market. 

Japan Oncology Drugs Market Segmentation  

The Japan oncology drugs market size is studied based on segment, drug class type, and indication. Based on drug class type, the market is divided into chemotherapy, targeted therapy, immunotherapy, hormonal therapy. By indication, it is categorized into blood cancer, breast cancer, gastrointestinal cancer, prostate cancer, lung cancer, skin cancer, ovarian cancer, cervical cancer, kidney cancer, and others. 

Segment Review

Based on drug class type, the targeted therapy segment occupied the largest Japan oncology drugs market share in 2018 owing to lesser side effects of the drugs as compared to other treatment options. This is due to the ability of targeted therapies to kill only malignant cells thereby exhibiting better treatment outcomes. In addition, higher efficacy and higher survival rates associated with the use of targeted therapy drugs are other reasons that fuel the growth of the market. The immunotherapy segment is expected to show fastest growth during the forecast period owing to surge in incidence of cancer worldwide and high unmet medical needs in some countries. Moreover, immunotherapy drugs are widely accepted as an ideal treatment option as these drugs are potentially harmless to the other living cells of the body, which makes them less toxic as compared to other modes of cancer therapies. Furthermore, continuous efforts in R&D to design and develop new immunotherapeutic for the treatment of various cancer types serves as a key factor for the Japan oncology drugs market growth.

Japan Oncology Drugs Market By Drug Class Type

Get more information on this report : Request Sample Pages

According to indication, the prostate cancer segment occupied the largest Japan oncology drugs market share in 2018. This is due to presence of huge geriatric population. The lung cancer segment is expected to experience fastest growth during the forecast period. This is due to technological developments in the field of cancer diagnostics and rise in the awareness related to the early diagnosis of cancer.

Japan Oncology Drugs Market By Indication

Get more information on this report : Request Sample Pages

The Japan oncology drugs market is highly competitive and the prominent players in the market have adopted various strategies for garnering maximum market share. These include collaboration, product launch, partnership, and acquisition. Major players operating in the market include Otsuka Holdings Co Ltd, Johnson and Johnson, Daiichi Sankyo Co Ltd, AstraZeneca plc, AbbVie Inc., Celgene Corporation, Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Astellas Pharma Inc., and Takeda Pharmaceutical Company Ltd

Key Benefits for Japan Oncology Drugs Market :

  • This report entails a detailed quantitative analysis along with the current Japan oncology drugs market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
  • The Japan oncology drugs market forecast is studied from 2019 to 2026. 
  • The market size and estimations are based on a comprehensive analysis of key developments in the Japan oncology drugs industry. 
  • A qualitative analysis based on innovative products facilitates strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market

Japan Oncology Drugs Market Segments:

By Drug Class Type

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy (Biologic Therapy)
  • Hormonal Therapy

By Indication

  • Blood Cancer
  • Breast Cancer
  • Gastrointestinal Cancer
  • Prostate Cancer
  • Lung Cancer
  • Skin Cancer
  • Ovarian Cancer
  • Cervical Cancer
  • Other Cancers
 

CHAPTER 1:    INTRODUCTION

1.1.    Report description
1.2.    Key benefits for stakeholders
1.3.    Key market segments
1.4.    Research methodology

1.4.1.    Secondary research
1.4.2.    Primary research
1.4.3.    Analyst tools and models

CHAPTER 2:    EXECUTIVE SUMMARY

2.1.    Key findings of the study
2.2.    CXO perspective

CHAPTER 3:    MARKET OVERVIEW

3.1.    Market definition and scope
3.2.    Key findings

3.2.1.    Top investment pockets
3.2.2.    Top winning strategies, 2018

3.3.    Porter’s five forces analysis
3.4.    Market dynamics

3.4.1.    Drivers

3.4.1.1.    Rise in incidence of cancer
3.4.1.2.    Surge in geriatric population

3.4.2.    Restraint

3.4.2.1.    Stringent approval process

3.4.3.    Opportunity

3.4.3.1.    Increase in number of pipeline drugs

3.4.4.    Impact analyses

CHAPTER 4:    ONCOLOGY DRUGS MARKET, BY DRUG CLASS TYPE

4.1.    Overview

4.1.1.    Market size and forecast

4.2.    Chemotherapy

4.2.1.    Key market trends, growth factors, and opportunities
4.2.2.    Market size and forecast,

4.3.    Targeted therapy

4.3.1.    Key market trends, growth factors, and opportunities
4.3.2.    Market size and forecast,

4.4.    Immunotherapy

4.4.1.    Key market trends, growth factors, and opportunities
4.4.2.    Market size and forecast,

4.5.    Hormonal therapy

4.5.1.    Key market trends, growth factors, and opportunities
4.5.2.    Market size and forecast,

CHAPTER 5:    ONCOLOGY DRUGS MARKET, BY INDICATION

5.1.    Overview

5.1.1.    Market size and forecast

5.2.    Blood cancer

5.2.1.    Key market trends, epidemiology, growth factors and opportunities
5.2.2.    Market size and forecast

5.3.    Breast cancer

5.3.1.    Key market trends, epidemiology, growth factors and opportunities
5.3.2.    Market size and forecast

5.4.    Gastrointestinal and urinary cancer

5.4.1.    Key market trends, epidemiology, growth factors and opportunities

5.4.1.1.    Market size and forecast

5.4.2.    GB/Cholangiocarcinoma

5.4.2.1.    Market size and forecast

5.4.3.    Bladder cancer

5.4.3.1.    Market size and forecast

5.4.4.    Pancreatic cancer

5.4.4.1.    Market size and forecast

5.5.    Prostate cancer

5.5.1.    Key market trends, epidemiology, growth factors and opportunities

5.5.1.1.    Market size and forecast

5.6.    Lung cancer

5.6.1.    Key market trends, epidemiology, growth factors and opportunities

5.6.1.1.    Market size and forecast

5.6.2.    Small cell lung cancer

5.6.2.1.    Market size and forecast

5.7.    Skin cancer

5.7.1.    Key market trends, epidemiology, growth factors and opportunities

5.7.1.1.    Market size and forecast

5.8.    Ovarian cancer

5.8.1.    Key market trends, epidemiology, growth factors and opportunities

5.8.1.1.    Market size and forecast

5.9.    Cervical cancer

5.9.1.    Key market trends, epidemiology, growth factors and opportunities

5.9.1.1.    Market size and forecast

5.10.    Kidney cancer

5.10.1.    Key market trends, epidemiology, growth factors and opportunities

5.10.1.1.    Market size and forecast

5.11.    Other cancers

5.11.1.    Key market trends, epidemiology, growth factors and opportunities

5.11.1.1.    Market size and forecast

CHAPTER 6:    COMPANY PROFILES

6.1.    ABBVIE INC.

6.1.1.    Company overview
6.1.2.    Company snapshot
6.1.3.    Operating business segments
6.1.4.    Product Portfolio
6.1.5.    Business performance
6.1.6.    Key strategic moves and developments: Global

6.2.    Astellas Pharma Inc.

6.2.1.    Company overview
6.2.2.    Company snapshot
6.2.3.    Operating business segments
6.2.4.    Product portfolio
6.2.5.    Business performance
6.2.6.    Key strategic moves and developments: Japan
6.2.7.    Key strategic moves and developments: Global

6.3.    AstraZeneca plc

6.3.1.    Company overview
6.3.2.    Company snapshot
6.3.3.    Operating business segments
6.3.4.    Product portfolio
6.3.5.    Business performance
6.3.6.    Key strategic moves and developments: Japan
6.3.7.    Key strategic moves and developments: Global

6.4.    Bristol-Myers Squibb Company

6.4.1.    Company overview
6.4.2.    Company snapshot
6.4.3.    Operating business segments
6.4.4.    Product portfolio
6.4.5.    Business performance
6.4.6.    Key strategic moves and developments: Global

6.5.    Celgene Corporation

6.5.1.    Company overview
6.5.2.    Company snapshot
6.5.3.    Operating business segments
6.5.4.    Product portfolio
6.5.5.    Business performance
6.5.6.    Key strategic moves and developments: Global

6.6.    Daiichi Sankyo Company, Limited

6.6.1.    Company overview
6.6.2.    Company snapshot
6.6.3.    Operating business segments
6.6.4.    Product portfolio
6.6.5.    Business performance
6.6.6.    Key strategic moves and developments: Japan
6.6.7.    Key strategic moves and developments: Global

6.7.    Hoffmann-La Roche AG

6.7.1.    Company overview
6.7.2.    Company snapshot
6.7.3.    Operating business segments
6.7.4.    Product portfolio
6.7.5.    Business performance
6.7.6.    Key strategic moves and developments: Japan
6.7.7.    Key strategic moves and developments: Global

6.8.    Johnson & Johnson (Janssen Pharmaceuticals, Inc.)

6.8.1.    Company overview
6.8.2.    Company snapshot
6.8.3.    Operating business segments
6.8.4.    Product portfolio
6.8.5.    Business performance
6.8.6.    Key strategic moves and developments: Japan
6.8.7.    Key strategic moves and developments: Global

6.9.    Otsuka Holdings Co., Ltd.

6.9.1.    Company overview
6.9.2.    Company snapshot
6.9.3.    Operating business segments
6.9.4.    Product portfolio
6.9.5.    Business performance
6.9.6.    Key strategic moves and developments: Japan
6.9.7.    Key strategic moves and developments: Global

6.10.    Takeda Pharmaceutical Company Ltd.

6.10.1.    Company overview
6.10.2.    Company snapshot
6.10.3.    Operating business segments
6.10.4.    Product portfolio
6.10.5.    Business performance
6.10.6.    Key strategic moves and developments: Japan
6.10.7.    Key strategic moves and developments: Global

LIST OF TABLES

TABLE 01.    JAPAN ONCOLOGY DRUGS MARKET, BY DRUG CLASS TYPE, 2018–2026 ($MILLION)
TABLE 02.    JAPAN ONCOLOGY DRUGS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 03.    ABBVIE: COMPANY SNAPSHOT
TABLE 04.    ABBVIE: OPERATING SEGMENTS
TABLE 05.    ABBVIE: PRODUCT PORTFOLIO
TABLE 06.    ASTELLAS: COMPANY SNAPSHOT
TABLE 07.    ASTELLAS: PRODUCT PORTFOLIO
TABLE 08.    ASTRAZENECA: COMPANY SNAPSHOT
TABLE 09.    ASTRAZENECA: OPERATING SEGMENTS
TABLE 10.    ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 11.    BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 12.    BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
TABLE 13.    CELGENE: COMPANY SNAPSHOT
TABLE 14.    CELGENE: OPERATING SEGMENTS
TABLE 15.    CELGENE: PRODUCT PORTFOLIO
TABLE 16.    DAIICHI-SANKYO: COMPANY SNAPSHOT
TABLE 17.    DAIICHI-SANKYO: OPERATING SEGMENTS
TABLE 18.    DAIICHI-SANKYO: PRODUCT PORTFOLIO
TABLE 19.    ROCHE: COMPANY SNAPSHOT
TABLE 20.    ROCHE: OPERATING SEGMENTS
TABLE 21.    ROCHE: PRODUCT PORTFOLIO
TABLE 22.    J&J: COMPANY SNAPSHOT
TABLE 23.    J&J: OPERATING SEGMENTS
TABLE 24.    J&J: PRODUCT PORTFOLIO
TABLE 25.    OTSUKA: COMPANY SNAPSHOT
TABLE 26.    OTSUKA: OPERATING SEGMENTS
TABLE 27.    OTSUKA: PRODUCT PORTFOLIO
TABLE 28.    TAKEDA: COMPANY SNAPSHOT
TABLE 29.    TAKEDA: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.    JAPAN ONCOLOGY DRUGS MARKET SEGMENTATION
FIGURE 02.    TOP INVESTMENT POCKETS
FIGURE 03.    TOP WINNING STRATEGIES: GLOBAL, 2017–2019
FIGURE 04.    TOP WINNING STRATEGIES: GLOBAL, BY YEAR, 2017–2019
FIGURE 05.    TOP WINNING STRATEGIES: JAPAN, 2017–2019
FIGURE 06.    TOP WINNING STRATEGIES: JAPAN, BY YEAR, 2017–2019
FIGURE 07.    LOW BARGANING POWER OF SUPPLIERS
FIGURE 08.    MODERATE THREAT OF SUBSTITUTES
FIGURE 09.    MODERATE THREAT OF NEW ENTRANTS
FIGURE 10.    MODERATE COMPETITIVE RIVALRY
FIGURE 11.    LOW BARGANING POWER AMONG BUYERS
FIGURE 12.    TOP IMPACTING FACTORS
FIGURE 13.    IMPACT ANALYSES
FIGURE 14.    NUMBER OF CANCER INCIDENCES IN 2018, JAPAN
FIGURE 15.    JAPAN BLOOD CANCER MARKET, 2018–2026 ($MILLION)
FIGURE 16.    JAPAN BREAST CANCER MARKET, 2018–2026 ($MILLION)
FIGURE 17.    JAPAN GASTROINTESTINAL CANCER MARKET, 2018–2026 ($MILLION)
FIGURE 18.    JAPAN GASTROINTESTINAL CANCER MARKET, FOR CHOLANGIOCARCINOMA, 2018–2026 ($MILLION)
FIGURE 19.    JAPAN GASTROINTESTINAL/URINARY CANCER MARKET, FOR BLADDER, 2018–2026 ($MILLION)
FIGURE 20.    JAPAN GASTROINTESTINAL/URINARY CANCER MARKET, FOR PANCREAS, 2018–2026 ($MILLION)
FIGURE 21.    JAPAN GASTROINTESTINAL/URINARY CANCER MARKET, FOR PROSTATE, 2018–2026 ($MILLION)
FIGURE 22.    JAPAN LUNG CANCER MARKET, 2018–2026 ($MILLION)
FIGURE 23.    JAPAN LUNG CANCER MARKET, FOR SMALL CELL LUNG CANCER, 2018–2026 ($MILLION)
FIGURE 24.    JAPAN SKIN CANCER MARKET, 2018–2026 ($MILLION)
FIGURE 25.    JAPAN OVARIAN CANCER MARKET, 2018–2026 ($MILLION)
FIGURE 26.    JAPAN CERVICAL CANCER MARKET, 2018–2026 ($MILLION)
FIGURE 27.    JAPAN KIDNEY CANCER MARKET, 2018–2026 ($MILLION)
FIGURE 28.    JAPAN OTHER CANCERS MARKET, 2018–2026 ($MILLION)
FIGURE 29.    ABBVIE: NET SALES, 2016–2018 ($MILLION)
FIGURE 30.    ABBVIE: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 31.    ABBVIE: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 32.    ASTELLAS: NET SALES, 2016–2018 ($MILLION)
FIGURE 33.    ASTELLAS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 34.    ASTELLAS: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 35.    ASTRAZENECA: NET SALES, 2016–2018 ($MILLION)
FIGURE 36.    ASTRAZENECA: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 37.    BRISTOL-MYERS SQUIBB: NET SALES, 2016–2018 ($MILLION)
FIGURE 38.    BRISTOL-MYERS SQUIBB: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 39.    BRISTOL-MYERS SQUIBB: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 40.    CELGENE: NET SALES, 2016–2018 ($MILLION)
FIGURE 41.    CELGENE: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 42.    CELGENE: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 43.    DAIICHI-SANKYO: NET SALES, 2016–2018 ($MILLION)
FIGURE 44.    DAIICHI-SANKYO: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 45.    DAIICHI-SANKYO: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 46.    ROCHE: NET SALES, 2016–2018 ($MILLION)
FIGURE 47.    ROCHE: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 48.    ROCHE: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 49.    J&J: NET SALES, 2016–2018 ($MILLION)
FIGURE 50.    J&J: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 51.    J&J: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 52.    OTSUKA: NET SALES, 2016–2018 ($MILLION)
FIGURE 53.    OTSUKA: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 54.    OTSUKA: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 55.    TAKEDA: NET SALES, 2016–2018 ($MILLION)
FIGURE 56.    TAKEDA: REVENUE SHARE BY REGION, 2018 (%)

 

 
 

Cancer is a large group of diseases that represent an abnormal growth of cells and tend to proliferate in an uncontrolled manner. Cancer is mostly named after the organ in which it initiates. For instance, lung cancer, breast cancer, colorectal, prostate cancer, and others. There are different treatments available for cancer such as chemotherapy, immunotherapy, and others. The management of cancer by the use of drugs is different in every patient as the treatment depends on the tumor progression.

The key factor responsible for the growth of the Japan oncology drugs market is increase in prevalence of cancer. Furthermore, the market growth is also propelled by surge in geriatric population, increase in collaboration between pharmaceutical companies for development of novel cancer drugs, and rise in awareness associated with early detection of cancer among populace. In addition, surge in geriatric population also contributes to the growth of the market as the elderly are more prone to certain cancers such as prostate cancer.

Moreover, rise in number of pipeline products is expected to provide lucrative opportunities during the forecast period. However, stringent approval process of oncology drugs in Japan hinders the growth of the market.

 

PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library, Subcription @ $649 T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry

Download Sample

Request Customization

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

FREQUENTLY ASKED
QUESTIONS?

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Japan Oncology Drugs Market

  • Data Pack
  • $1,845  $1,624
  • Restricted to one authorized user
  • One print only
  • Available in Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $2,580  $2,064
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $3,099  $2,324
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $4,322  $3,025
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Access
  • $0.00
  • Published Content E-Access
  • Company Profiles E-Access
  • Newly Added Content Access
  • 10 PDF Downloads
  • 5 Excel Data Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly
    ,This title and over 12000 thousand more,available with Avenue Library, Subcription @ $649 T&C*

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 
Download Sample